As the world yearns to return to normal life after more than a year of a pandemic, countries are seeking to supply vaccines that should slow – and hopefully stop – the spread. coronavirus.
The success of this will depend on a number of factors – on the production and transportation of the billions of doses that provide it. rich nations do not monopolize the global supply of vaccines and, most importantly, the actual receipt of doses in the hands of the people.
The charts and maps below will be updated to show the most recent data on the largest prevalence of vaccination in history, in the United States and worldwide.
Depending on how quickly the vaccine is given to humans, there are noticeable differences.
The first two vaccines approved for emergency use in the US, developed by companies Pfizer / BioNTech and Modernintended for two-dose intake in a few weeks. Johnson and Johnson the vaccine, approved for use in late February, requires only one dose. Thus, vaccinating everyone in the U.S. would eventually mean giving 100 to 200 doses per 100 people in each state and territory – or a total of 330 to 660 million doses for the entire nation. This is Fr. a huge logistical challenge.
As the Biden administration took on the promise of strengthening federal coordination of vaccine distribution, the number of daily injections steadily increased, reaching a peak on April 3 of more than 3 million doses per day. In May, faced with a sharp decline in the number of people, Biden announced new strategy with the aim of vaccinating more hard-to-reach communities, moving from mass vaccination centers to more mobile clinics and admission to pharmacies. However, there are fears that vaccination is getting poorer people and community color behind.
Search this table and find out how your state or territory works on these key vaccine measures.
Vaccine deployment schedule
This chart shows the number of vaccines administered per 100 people in each state since early 2021. There are three main states and national figures of the United States. Enter the name of any other U.S. state or territory in the search bar and select to add to the chart.
This chart shows the daily number of vaccine doses administered to humans across the country from early 2021. Due to data jumps due to lagging in reporting, the bar showing the 7-day moving average of these doses gives a clearer idea of whether it is accelerating or slowing down. spread.
Location of the vaccine by country
On this map there are more countries showing vaccine doses per 100 people as these figures are reported more widely.
In most countries with the highest levels of vaccination, the population is still very small. The United States is ahead of most major countries in the spread of vaccines. Search and navigate through this table to see how things are in each nation.
Vaccine deployment schedule
This chart shows the number of vaccines administered per 100 people in each country from the beginning of 2021. Enter the name of any country in the search bar and select to compare its terms with the US and the other three leading countries in the world to distribute vaccines. Only countries that have started their vaccination campaigns will appear.
This chart shows the reported number of daily doses of vaccines that people around the world receive. Because of the jumps due to the lag in reporting, the bar showing the 7-day moving average of the given doses gives a clearer idea of whether the deployment is accelerating or slowing down.
Status of leading vaccines
This table shows the status of the leading vaccines against COVID-19, shows the permits for use in the United States and other markets, as well as prices from information on purchase agreements compiled by UNICEFwhere there is.
Vaccines from Pfizer / BioNTech and Moderna, clinical trial results show they are more than 90% efficiency in disease prevention is based on new technology which provides an RNA sequence that causes our own cells to produce viral proteins, eliciting an immune response.
The disadvantage is that these vaccines are more expensive than vaccines made by splicing genetic material from a coronavirus into a disabled version of another virus, such as that produced by the Anglo-Swedish company AstraZeneca, based on research from Oxford University,, Johnson and Johnson, and Russia Gamaleya Research Institute.
Other leading vaccines are based on inactivated versions of the coronavirus, a long-standing approach to making vaccines or subunits of proteins from the virus.
Jeremy Singer-Vine contributed to this story.